Related Experiment Videos

Visceral and cutaneous leishmaniasis in an European paediatric population

M Mattot1, J Ninane, G Bigaignon

  • 1Department of Paediatrics, Cliniques Universitaires Saint-Luc, Brussels.

Acta Clinica Belgica
|January 1, 1992
PubMed

Insights

This study treated six children with leishmaniasis using Glucantime and Lomidine. Both visceral and cutaneous leishmaniasis cases showed positive serology and improved with treatment, with minimal reversible side effects.

Area of Science:

  • Pediatric infectious diseases
  • Parasitology
  • Clinical pharmacology

Background:

  • Leishmaniasis is a significant parasitic disease affecting children globally.
  • Effective treatment protocols for pediatric leishmaniasis are crucial for improving patient outcomes.
  • Understanding drug efficacy and safety in pediatric populations is essential.

Observation:

  • Six pediatric patients diagnosed with leishmaniasis (visceral and cutaneous) were treated.
  • Diagnosis involved bone marrow examination for visceral leishmaniasis and skin biopsy for cutaneous leishmaniasis.
  • All patients presented with positive serology at diagnosis.

Findings:

  • Combination therapy with Glucantime and Lomidine was used for visceral leishmaniasis.
  • Glucantime monotherapy was administered for cutaneous leishmaniasis.
  • All six children demonstrated clinical improvement following treatment.

Implications:

  • Glucantime and Lomidine demonstrate efficacy in treating pediatric leishmaniasis.
  • The observed side effects (cough, fever, supraventricular premature beats) were transient and reversible.
  • These findings support the use of these antimonial drugs in pediatric leishmaniasis management.

Related Concept Videos